Company intelligence / Profile preview
Bioasis Technologies
Guilford, Connecticut, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Bioasis' xB^3 platform enables delivery of therapeutic drugs across the blood-brain barrier and has demonstrated proof-of-concept in preclinical models; the company licenses this technology to biotech and pharma partners and continues developing in-house neurotherapeutics.
- Therapeutic areas
- OncologyNeurologyMetabolic Disorders
- Modalities
- PeptidesProteinCarrier-based drug delivery
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Multiple biotech/pharma licensing partners (details not specifically disclosed)known history of out-licensing to advance neurotherapeutic programs
Beyond the preview
Go deeper on Bioasis Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioasis Technologies.